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Abstract
Purpose—We applied whole genome sequencing to children diagnosed with neoplasms and 
found to carry apparently balanced constitutional translocations, to discover novel genic 
disruptions.
Methods—We applied SV calling programs CREST, Break Dancer, SV-STAT and CGAP-CNV, 
and developed an annotative filtering strategy to achieve nucleotide resolution at the 
translocations.
Results—We identified the breakpoints for t(6;12) (p21.1;q24.31) disrupting HNF1A in a patient 
diagnosed with hepatic adenomas and Maturity Onset Diabetes of the Young (MODY). 
Translocation as the disruptive event of HNF1A, a gene known to be involved in MODY3, has not 
been previously reported. In a subject with Hodgkin’s lymphoma and subsequent low-grade 
glioma, we identified t(5;18) (q35.1;q21.2), disrupting both SLIT3 and DCC, genes previously 
implicated in both glioma and lymphoma.
Conclusions—These examples suggest that implementing clinical whole genome sequencing in 
the diagnostic work-up of patients with novel but apparently balanced translocations may reveal 
unanticipated disruption of disease-associated genes and aid in prediction of the clinical 
phenotype.
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INTRODUCTION
Although potentially harmless, balanced translocations can alter gene expression or function 
if the breakpoints occur within genes or regulatory regions. Balanced de novo translocations 
(not inherited from a parent) were seen with a prevalence of ~0.08% in a large cohort of 
prenatal cytogenetic results1. Translocations can result in gene fusions or disruptions, and 
both can be identified through whole genome sequencing with structural variation (SV) 
programs reporting translocation events. We used paired-end Illumina whole genome 
sequencing (WGS) on two subjects with constitutional balanced translocations, applied three 
SV calling algorithms (CREST, Break Dancer and SV-STAT), and developed an annotative 
filtering strategy to identify the precise breakpoints of novel genic disruptions2–4. Both 
patients and parents (when available) were entered into a human subjects protocol approved 
by the institutional review board of Baylor College of Medicine (BCM).
The first patient, FCP637, is a 12 year old girl with dysmorphic craniofacial features, seizure 
disorder, vesicoureteral reflux, patent foramen ovale and mildly dilated aortic root, 
Hashimoto thyroiditis, moderate speech delay (receptive language superior to expressive), 
poor speech articulation with normal hearing, friendly demeanor, subclinical seizures, and 
hypotonia. Diffuse hepatic adenomas were discovered incidentally and confirmed by needle 
biopsy. Perturbation of HNF1A (TCF1) is associated with familial hepatic adenomas, and 
with maturity onset diabetes of the young type 3 (MODY 3, MIM600496, MIM142410)5. 
MODY 3 was diagnosed approximately two years after adenoma discovery. Peripheral 
blood karyotype revealed an apparently balanced translocation between 6p11.1 and 12q24.2. 
Karyotype analysis of both parents was normal, confirming the translocation was de novo. 
Clinical Sanger sequence analysis of HNF1A was normal, and an oligonucleotide 
chromosomal microarray analysis (BCM, Molecular Genetics Laboratory) with exon 
coverage of HNF1A showed no copy number variation (CNV), gain or loss of material. 
However, the microarray results included a microdeletion of chromosome 17q21.31, 
encompassing 0.341 Mb – 1.328 Mb. This results in a well-described microdeletion 
syndrome, (Koolen-de Vries syndrome, MIM610443) which includes many of the 
developmental problems seen in the patient.
The second patient, FCP672, is a male, diagnosed at age 5 by lymph node biopsy, with 
classical Hodgkin’s Lymphoma of mixed cellularity with interfollicular growth pattern 
(MIM236000). The patient displayed unexplained growth deceleration and obesity, but no 
apparent developmental delay. Bone marrow at the time of diagnosis demonstrated an 
apparently balanced translocation t(5;18) (q35.1;q21.2) in all lymphoma cells analyzed. 
Subsequent peripheral blood and skin fibroblast karyotype analyses demonstrated the 
translocation in all cells, confirming it was constitutional. A focused chromosomal analysis 
of both parents found no rearrangements for chromosomes 5 or 18. Two chromosomal 
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microarrays were performed (version V7.2CMA, repeated in 2013 as CMA-HR
+SNP(V9.1.1)) and failed to detect loss or gain of genomic material in the region of the 
translocation. After completing treatment for lymphoma, the patient was diagnosed by MRI 
with a brain lesion suggestive of low-grade glioma and is being followed by serial imaging 
without biopsy.
METHODS
Genomic DNA from both patients and one maternal parental sample (FCP664, the mother of 
FCP672) underwent WGS (Illumina, 100bp paired-ends, 400bp insert size, 30× coverage) at 
BCM Human Genome Sequencing Center, following previously described protocols and 
quality metrics, with alignment to HG196. SV: We applied CREST, SV-STAT and Break 
Dancer (using default parameters, apart from Break Dancer q>=50) and intersected outputs 
using 600bp windows. Filtering metrics were as follows: CREST: >=4 right/left soft clips 
and >=20 reads coverage. Break Dancer: >=20 anomalous read pairs, SV-STAT: “PASS” 
filter calls only. We excluded translocations between autosomal and X/Y chromosomes due 
to mis-mapping. As controls, we used the BAB195 48× whole genome7 and an additional 
set of 69 samples from normal tissues of adults from The Cancer Genome Atlas. We 
removed any proband translocation within 600bp of control translocations. The analyst was 
aware of t(6;12) (p11.1;q24.2) reported in FCP637, but was blinded to the cytogenetic 
breakpoints for FCP672. CNV: We applied CGAP-CNV, a local whole genome copy 
number program, to obtain microdeletion breakpoint windows. These were manually refined 
using Integrative Genomics Viewer (IGV). SNV and INDELS: For samples and a large set of 
controls (1079 randomly selected non-tumor whole exomes from the Atherosclerosis Risk in 
Communities (ARIC) cohort, run on the same design), variants were called with ATLAS 
Suite and Pindel (<=200bp indels), and annotated with ANNOVAR, dbSNP, COSMIC and 
Exome Variant Server. Variants were filtered for >=20%/30% variant allele fraction in WE 
and WGS, respectively, <=1% dbSNP minor allele frequency and <=1.5% presence in 
control set. Variants were manually reviewed in IGV, with the BAB195 40× whole genome 
as a visual control. Breakpoint Reporting: We utilize the recently described Next-Gen 
Cytogenetics nomenclature in reporting breakpoints from cytogenetic karyotype and whole 
genome sequencing8. Breakpoint Databases Queried: Mittelman Database, Atlas of 
Genetics and Cytogenetics in Oncology and Haematology, TICdb and DACRO. Calling, 
annotation and database sources can be found by an internet search of listed names; for 
brevity we could not list individual references.
RESULTS
The breakpoints for the proband with MODY3 and hepatic adenomas (FCP637), using the 
newly proposed genomic nomenclature, are: 46,XX,t(6;12)(p11.1;q24.2)dn.seq[GRCh37/
hg19]t(6;12)(12qter→12q24.31(121,420,346)::6p21.1(44,758,577)→6qter;
12pter→12q24.31(121,420,33{1–2})::6p21.1(44,758,57{3–2})→6pter)dn
On chr6, this is a non-genic region approximately 35 kilobases (kb) away from SUPT3H, 
and approximately 336 kb from CDC5L in the telomeric direction. On chr12, the breakpoint 
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occurs in the first intron of HNF1A, likely disrupting gene function as the open reading 
frame is broken into two segments (Figure 1A, Table S1).
For FCP672, the proband with Hodgkin's lymphoma and subsequent putative low-grade 
glioma, the breakpoints are: 46,XY,t(5;18)(q35.1;q21.2)dn.seq[GRCh37/hg19] t(5;18)
(5pter→5q34(168,236,81{0–3})::18q21.2(50,099,{299–302})→18qter;
18pter→18q21.2(50,099,30{2–3})::5q34(168,236,81{5–6})→5qter)dn.
On chromosome 5, the breakpoint occurs in intron 8 of SLIT3, and the first intron of DCC 
on chromosome 18. DCC is forward transcribed, while SLIT3 is transcribed in the negative 
direction. Again, from reconstructing the derivative chromosomes (Figure 2A, Table S1), we 
reason both DCC and SLIT3 open reading frames are disrupted.
We validated translocations using PCR assays (Figures 1 and 2), followed by Sanger 
sequencing. As expected, all samples from the patients, mother and control lines contain 
PCR products from intact copies of the involved chromosomes. PCR reactions spanning the 
putative breakpoints reveal sequencing that aligns to re-constructed derivatives in the 
probands. For t(6;12) (p21.1;q24.31), Sanger sequencing of the der6 product revealed an 
overlap of only 2 bp between chr6 and chr12: 
AGTATAAAAACAGAGCTAGGATTAGGATG with a 5 bp deletion of chr6 (Figure 1B). 
For der12 product, Sanger sequencing results show a deletion of 13bp in the breakpoint 
region, and a 12 bp region of homology to both chr6 and chr12, adjacent to the translocation 
breakpoint. This indicates a balanced translocation with minimal sequence loss. Similarly, 
for t(5;18) (q34;q21) (Figure 2B), we find a 4 bp region of homology (CACA) between chr5 
and chr18 at the region of the breakpoint. There is a 2 bp deletion on chr5, and no loss on 
chr18. These WGS results showing nearly precise breakpoints are consistent with the normal 
microarray results.
As mentioned, FCP637 carries a well-described heterozygous microdeletion detected within 
a megabase range by clinical arrayCGH. We determined the microdeletion breakpoints as: 
46,XX.arr[hg19]17q21.31.seq[GRCh37/hg19]del(17)
(pter→q21.31(43691189)::q21.31(44354365) →qter) (Figure S1). This is a ~663kb span, 
which is typical of previously reported microdeletions, and deletes the reported causal gene, 
KANSL1.
To determine if the clinical phenotypes might result from mutations near the translocation 
breakpoints, we reviewed the single-nucleotide variation (SNVs) and insertions and 
deletions (INDELs) within 1kb of transcription start/stop from whole-exome and genome for 
DCC, SLIT3 and HNF1A. No rare coding or intronic variants that passed visual inspection 
were identified in HNF1A, and the noncoding region approximately 35kb downstream 
SUPT3H was not further analyzed for variants. Interestingly, RUNX2 is ~537kb from the 
chromosome 6 breakpoint, and CDC5L is ~326kb upstream. RUNX2 is a global 
transcriptional regulator (MIM600211); CDC5L is similar in sequence to cell-cycle 
regulatory genes (MIM602868). Position effects, such as distal gene disruptions ablating or 
inducing long-range cis-regulation, have been reported in a t(6;7) (p21.1;q36) breakpoint 
~735kb upstream of RUNX2 (although the proband phenotype is markedly dissimilar to 
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ours)9. Position effects present a challenge due to large numbers of possible affected genes, 
and we did not have RNA-sequencing data for further analysis. For SLIT3, only one rare 
(rs34260167, MAF=.006) maternal (FCP664) missense variant in exon 18 of SLIT3 (chr5, 
168180047 C>T, S629N) was found in whole exome, and no rare variants were identified in 
the proband FCP672. Whole genome variants produced far more results (>2k per 
individual), but after filtering and visualization, we found only the above maternal coding 
variant and a novel intronic variant at the site of the translocation in SLIT3 (chr5, IVS8, 
168236814 A>C). All other variants were novel intronic events of unknown significance 
(~140 per individual).
DISCUSSION
We identified two novel disruptive constitutional translocations occurring in introns of 
HNF1A, SLIT3 and DCC. We find no previous reports of a constitutional balanced 
translocation involving HNF1A. The prior knowledge of HNF1A underlying MODY3 with 
hepatic adenomas strongly supports our novel finding of HNF1A disruption caused by a 
translocation as the underlying genetic defect in FCP6375. We found a single report of an 
RNA-seq gene fusion in sarcoma tumors involving HNF1A and CMKLR1 genes, both genes 
on chr1210, and two prior reports identified constitutional balanced translocations in other 
forms of MODY-diagnosed individuals, one affecting HNF4A [t(3;20) (p21.2;q12)]11 and 
one involving MPP7, which shares functional overlap with HNF4A [t(7;10) (q22;p12)]12. 
Our finding emphasizes the benefits of obtaining intronic and nongenic sequences through 
whole genome sequencing, as in this case clinical exon tests of HNF1A did not find coding 
mutations, and arrayCGH did not indicate any material loss of HNF1A.
In addition to reports of germline variants of HNF1A (point mutations and small frame shift 
mutations) in MODY3 patients, Bluteau et. al. reports bi-allelic mutations of HNF1A in 
adenomas of affected individuals, indicative of a two-hit predisposition model13. 
Unfortunately there was insufficient tissue from the diagnostic biopsy to look for alterations 
of HNF1A in the hepatomas.
The WGS sequencing data fully resolved breakpoints of the 17q21.31microdeletion, 
consistent in size and genomic region to other reports. We find no other published cases of 
MODY3 and hepatic adenomas concurrent with Koolen-de Vries syndrome; these two 
conditions appear to be the result of one patient carrying two unrelated genomic events 
similar to recent reports from exome sequencing tests14.
We find no previous report of a constitutional balanced translocation disrupting both DCC 
and SLIT3. However, we have identified reports with translocations in the same or similar 
cytobands (5q34 and 18q21) in hematological malignancies (Table S2). The analyses 
focused on BCL2 in 18q21, however, the translocations were not characterized to gene-
resolution. DCC (Deleted in Colorectal Cancer) at 18q21 has been extensively studied as a 
tumor suppressor in colorectal cancers, but has also shown loss in lymphoid malignancies15 
and specifically in Hodgkin's Lymphoma16. Likewise, SLIT3 has been reported to undergo 
epigenetic regulation in cancers and is down-regulated in gliomas17, which is of relevance to 
the evidence of low-grade glioma on MRI imaging. Dickinson et al. showed SLIT3 
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inactivation via 5’ hypermethylation in 21/60 (~35%) glioma tumors17. Additionally, a 
miRNA (mir-218-2) was recently reported in SLIT3 intron 22, and mir-218-2 expression 
decreased with concurrent reduction of SLIT3 transcript18. Our t(5;18) (q34;q21) breakpoint 
is upstream of mir-218-2, and thus may disrupt miRNA transcription. The implications for 
cancer and DCC and the UNC5s/SLITs/ROBOs gene families have been recently 
reviewed19. Our work suggests further analysis of germline changes in SLIT3 should be 
considered in glioma patients.
In clinical genetics, the counseling and prediction of future clinical manifestations for a 
child with a previously uncharacterized balanced translocation has been challenging. 
Although both of the patients described had de novo translocations, previous work identified 
balanced translocations involving chromosome 3 transmitted through multiple generations, 
resulting in autosomal dominant familial renal cell cancer20. The integration of clinical 
whole genome sequencing, with appropriate data analysis for precise mapping of 
rearrangements, into diagnostic testing may provide important knowledge of the genes 
disrupted by balanced translocations and their potential role in disease manifestation. 
Current pediatric practice does not routinely include whole genome sequencing, particularly 
for balanced (as based on normal microarray analysis) or de novo balanced translocations 
lacking overt phenotypes. Our findings emphasize the need to resolve to base-pair resolution 
the breakpoints of constitutional balanced translocations by whole genome sequencing to 
provide optimal care.
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Figure 1. Translocation Characterization and PCR Confirmation of t(6;12) (p21.1;q24.31)
(A) Depicting the derivative chromosomes and gene re-arrangements. The der6 allele 
has HNF1A exons 2 to 10 in the reverse direction and ~ 35kb of nongenic sequence from the 
terminus of SUPT3H. The der12 allele displays forward transcription of HNF1A ending in a 
large noncoding region of chr6, prior to the CDCL5 gene, which is transcribed on the 
opposite strand. (B) Breakpoint Characterization: There is a 2bp microhomology at the 
breakpoint (CA, orange), deleted in a 5bp deletion on chr6 (purple and orange underline). A 
13bp deletion occurs on chr12 (purple underline), maintaining the CA microhomology. 
Arrows detail the breakpoint bases, with from the GRCh37 reference sequence on the side. 
(C) PCR Validation: Primers (6Fb and 6Rb; 12Fb and 12Rb) amplified the wild type 
chromosomes 6 and 12. The proband's mother (FCP638) and a Thousand Genomes sample 
(HG117) were also tested. Pairing primers 6Fb with 12Fb and 6Rb with 12Rb amplifies the 
expected translocation products in the proband.
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Figure 2. Translocation Characterization and PCR Confirmation of t(5;18) (q35.1;q21.2)
(A) The der5 allele displays exons 9–36 through the terminus of SLIT3, joined in intron 8 of 
SLIT3 and intron 1 of DCC, with DCC exons 2 through 29 in the opposite direction. The 
der18 allele shows the 1st exon of DCC in the forward direction, ending in intron 8 of SLIT3, 
which is transcribed in the opposite direction. (B) Breakpoint Characterization: There is a 
4bp region of homology between chr5 and chr18 at the breakpoint (CACA, orange), with a 
2bp deletion on chr5 (purple underline). On chr18, there is no loss of genomic material. 
Arrows and coordinates detail the breakpoint bases from the GRCh37 reference sequence. 
(C) PCR Validation: Primers (5Fb and 5Rb; 18Fb and 18Rb) amplified the wildtype 
chromosomes 5 and 18. The proband's mother (FCP664) and a Thousand Genomes sample 
(HG117) were also tested. Pairing primers 5Fb with 18Rb and 5Rb with 18Fb amplifies the 
expected translocation product. Nested PCR was used to confirm the der18 product and 
eliminate non-specific bands.
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